title: Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis.
abstract: BACKGROUND
  It has been reported that topical application of imiquimod 5% cream induces interferon-alpha, an antifibrotic cytokine.
  
  
  OBJECTIVE
  To determine the tolerability and effectiveness on the cosmetic outcome of the application of imiquimod to postsurgical excision sites.
  
  
  METHODS
  A prospective, double-blinded, randomized, vehicle-controlled trial was conducted among 20 patients with two skin lesions clinically diagnosed as melanocytic nevi. Imiquimod 5% cream was applied to one of the sutured surgical wounds starting the night of the excision nightly for a period of 4 weeks. The second sutured excision site was treated with vehicle cream. Scar cosmesis, erythema, pigmentary alterations, induration, tenderness, and pain were assessed using a visual analogue scale 2, 4, and 8 weeks after surgery.
  
  
  RESULTS
  Eighteen subjects completed the study, with a total of 36 excision sites; no wound site dehisced, and no signs of infection were noted. Surgical wounds treated with imiquimod had more erythema, pigmentary alterations, and lower cosmesis rated by the investigator compared with wounds treated with placebo, both becoming nonsignificant in further evaluations. For pigmentary alterations, induration, and cosmesis rated by the patients, no statistically significant difference between treatment groups was observed at week 8.
  
  
  CONCLUSIONS
  Treatment of surgical excision-site wounds with imiquimod was well tolerated and without serious adverse events. Evaluations for cosmesis of placebo-treated surgical sites were better than imiquimod-treated sites at week 8, becoming nonsignificant later.
authors.affiliation: Department of Dermatology and Cutaneous Surgery, University of Miami-Miller School of Medicine, Miami, Florida, USA. bberman@med.miami.edu
authors.forename: Brian
authors.initials: B
authors.lastname: Berman
authors.forename: Stacy
authors.initials: S
authors.lastname: Frankel
authors.forename: Adriana M
authors.initials: AM
authors.lastname: Villa
authors.forename: Claudia C
authors.initials: CC
authors.lastname: Ramirez
authors.forename: Varee
authors.initials: V
authors.lastname: Poochareon
authors.forename: Keyvan
authors.initials: K
authors.lastname: Nouri
mesh_terms: D000293:Adolescent; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002921:Cicatrix / Q000188:drug therapy*; D004311:Double-Blind Method; D004954:Esthetics; D005260:Female; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009508:Nevus, Pigmented / Q000601:surgery*; D009824:Ointments; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000634:Aminoquinolines; D007369:Interferon Inducers; D009824:Ointments; D000077271:Imiquimod